Access
This article is part of Nature's premium content.
Please note this is News in Brief, and so will be a short article.
Published online 7 May 2008 | 453, 145 (2008) | doi:10.1038/453145c
News in Brief
Drug firm turns spotlight on basic systems biology
To read this story in full you will need to login or make a payment (see right).
Please note this is News in Brief, and so will be a short article.
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
This could be read as follows: until now, the bigpharm was able to sustain its profits selling ideology only (like the diet-heart hypothesis). Profits have prevented scientific advance for the last 50 years. Now that profits associated to ideology-based medicine reached its limit, we, scientists, are being given the chance of asking real questions about pathophisiology and diseases causation. Thank you very much!
This could be read as follows: until now, the bigpharm was able to sustain its profits selling ideology only (like the diet-heart hypothesis). Profits have prevented scientific advance for the last 50 years. Now that profits associated to ideology-based medicine reached its limit, we, scientists, are being given the chance of asking real questions about pathophisiology and diseases causation. Thank you very much!
Systems biology can be of two "types", computational systems biology and biological systems biology. It is not clear from the news item if drug firms in general and Pfizer in particular is interested only in computational analysis of existing data or the interest is also towards generating systems level primary data.